title: Nonpharmacologic approaches for the treatment of hyperlipidemia.
abstract: Coronary heart disease (CHD) is the leading cause of death in the United States. Dyslipidemias, like decreased high-density lipoprotein (HDL) and increased low-density lipoprotein (LDL), have been linked through epidemiologic and experimental studies with the development of atherosclerosis and an increased risk of CHD. The introduction of various classes of lipid-lowering drugs, especially the hydroxymethylglutaryl-coenzyme-A-reductase inhibitors (statins), has allowed for effective treatment of hyperlipidemia. This article reviews the following nonpharmacologic approaches to hyperlipidemia: LDL apheresis, surgery, the emergence of HDL as a therapeutic target, gene therapy, and finally, the possibility of developing a vaccine against atherosclerosis.
authors.affiliation: Department of Medicine, Mayo Clinic/Mayo Clinic School of Medicine, Rochester, Minnesota, USA.
authors.forename: Tanaz
authors.initials: T
authors.lastname: Kermani
authors.forename: William H
authors.initials: WH
authors.lastname: Frishman
mesh_terms: D016632:Apolipoprotein A-I / Q000008:administration & dosage / Q000235:genetics; D001324:Autoantigens / Q000008:administration & dosage; D001781:Blood Component Removal; D008076:Cholesterol, HDL / Q000008:administration & dosage; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006938:Hyperlipoproteinemia Type II / Q000628:therapy; D007082:Ileum / Q000601:surgery; D016896:Treatment Outcome; D014611:Vaccination
chemical_list: D016632:Apolipoprotein A-I; D001324:Autoantigens; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL